Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Miscellaneous indications for extracorporeal photochemotherapy (ECP).
Fingolimod (Gilenya) licence extended
Life-threatening asthma attack during prolonged fingolimod treatment: case report.
Alemtuzumab Therapy for Multiple Sclerosis.
A Genome-Wide Integrative Genomic Study Localizes Genetic Factors Influencing Antibodies against Epstein-Barr Virus Nuclear Antigen 1 (EBNA-1).
Results of a phase II placebo-controlled randomized trial of minocycline in acute spinal cord injury.
Cutting Edge: TNF Receptor-Associated Factor 4 Restricts IL-17-Mediated Pathology and Signaling Processes.
Deaths and disability from natalizumab are no longer tolerable: No - (they can be avoided).
Lysoglycerophospholipids in chronic inflammatory disorders: The PLA(2)/LPC and ATX/LPA axes.
Role of Venoplasty for Treatment of Multiple Sclerosis: Value of Open-label Studies and Surrogate Treatment Outcomes.
[Research progress of the selective sphingosine-1-phosphate receptor 1 agonists].
Pre-existing T- and B-cell defects in one progressive multifocal leukoencephalopathy patient.
NMO spectrum presenting as partial myelitis.
Resveratrol effects on astrocyte function: Relevance to neurodegenerative diseases.
25-Hydroxycholecalciferol status in plasma is linearly correlated to daily summer pasture time in cattle at 56°N.
Effects of Imatinib Mesylate in Mouse Models of Multiple Sclerosis and In vitro Determinants.
Hyperconnectivity is a Fundamental Response to Neurological Disruption.
Dual effects of daily FTY720 on human astrocytes in vitro: relevance for neuroinflammation.
Th1 not Th17 cells drive spontaneous MS-like disease despite a functional regulatory T cell response.
[The role of chronic venous insufficiency in the pathogenesis of brain diseases].
Home-based exercise program and fall-risk reduction in older adults with multiple sclerosis: phase 1 randomized controlled trial.
The impact of walking speed on the effects of functional electrical stimulation for foot drop in people with multiple sclerosis.
Neurocardiogenic Pulmonary Oedema: Initial Presentation of Multiple Sclerosis.
Impact of Pharmacotherapy on Cognitive Dysfunction in Patients with Multiple Sclerosis.
Natalizumab in spinal multiple sclerosis in a daily clinical setting.

Pages